Companies › Restem
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Immunology; next expected readout Sep 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ULSC Allogeneic umbilical cord lining-derived stem cells | – | Phase 2 | Idiopathic Inflammatory Myositis (IIM); FSHD - Facioscapulohumeral Muscular Dystrophy | Sep 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07160205 | ULSC | Phase 2 | Idiopathic Inflammatory Myositis (IIM) | Immunology | Sep 2028 |
| NCT07086521 | ULSC | Phase 1 | FSHD - Facioscapulohumeral Muscular Dystrophy | Immunology | Sep 2029 |
No annotated target.
–
Xentria Cellcolabs Clinical SPV EHL Bio Nature Cell Throne Biotechnologies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.